The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
Additionally, the FDA Advisory Committee voted in support of approval for Pfizer's maternal RSVpreF vaccine candidate in May 2023; the PDUFA decision date is expected in August 2023.13 Although both GSK’s and Pfizer's RSV vaccines for use in older adults recently received approval from the FDA...
To date, GSK's RSV vaccine has been approved for adults aged 50-59 at increased risk in 35 countries, including the US, with regulatory decisions for other geographies undergoing review. About GSK's RSV vaccine Respiratory Syncytial Virus Vaccine, Adjuvanted recombinant, contains recombinant RSV gl...
Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its regulatory application to extend the indication of its respirator...
“A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older...
are at high risk for severe disease caused by RSV. Today's approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA's continued commitment to facilitating the development of safe and effective vaccines for...
GSK’s RSV older adult vaccine is not currently approved anywhere outside the US. The proposed trade name remains subject to regulatory approval outside the US. A clinical trial that aims to expand the population who may benefit from RSV vaccination into ad...
The article offers information on advancements in vaccine technology, particularly the FDA approval of the first respiratory syncytial virus (RSV) vaccine for use in older individuals. It also discusses breakthroughs in RSV vaccine development; the history of RSV vaccine ...
By 6 months, the vaccine still was still 70% effective against serious illness. "As a pediatrician, we haven't had any treatment for RSV my whole career and way before then, and so we would be hopeful that if there are options for treatment, that's huge for kids," said Dr. ...
Vaccines Protecting people from serious disease for well over 100 years Innovation Innovation is at the heart of achieving our purpose We use cookies We use cookies to enhance your website experience. Some cookies are necessary to ...